Press Releases

GlobeNewswire, Inc.

Delivers Record Q2 Net Income of $26.2 Million and EPS/ Adjusted EPS of $1.21/ $1.32; Declares Quarterly Dividend of $0.35 Per Share, Representing the Company’s 19th Consecutive Distribution Expands Fleet Renewal Program to $591 Million Across...

GlobeNewswire, Inc.

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- On July 24, 2026, Zevra Therapeutics (ZVRA) shares fell approximately 24% after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing...

GlobeNewswire, Inc.

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a...

GlobeNewswire, Inc.

First Streaming and Cloud Services agreement drives Q2 results above outlook Annualized recurring revenue1 at all-time high of $626 million, up 13% YoY Company raises full year 2026 revenue outlook by $85 million WILMINGTON, Del., July 30, 2026...

GlobeNewswire, Inc.

Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 Launched Expanded Access Program (EAP) for bitopertin for...

GlobeNewswire, Inc.

Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007's potential in MASH, type 2 diabetes, and other...

GlobeNewswire, Inc.

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with...

GlobeNewswire, Inc.

MONACO, July 30, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE: STNG) ("Scorpio Tankers" or the "Company") today reported its results for the three and six months ended June 30, 2026. The Company also announced that its board of directors...

GlobeNewswire, Inc.

Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2...

GlobeNewswire, Inc.

Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from 2Q25 reflecting continued strong physician...

GlobeNewswire, Inc.

~1.7 million total VOQUEZNA® prescriptions filled to date Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025 Initiating Phase 3 clinical...

GlobeNewswire, Inc.

For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025 RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the second quarter 2025 and a 24%...

GlobeNewswire, Inc.

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD® U.S. net sales increased 52% to a new all-time...

GlobeNewswire, Inc.

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial launch of AQVESME in thalassemia, with 442...

EIN Presswire

MARBELLA, SPAIN, July 30, 2026 /⁨EINPresswire.com⁩/ -- Designer Villas in Spain Announces Strategic Investment Partnership with JTA International Investment Holding for Ultra-Luxury Residential Development in Marbella Designer Villas in Spain is...

GlobeNewswire, Inc.

PORTLAND, Tenn., July 30, 2026 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, announced today its...

GlobeNewswire, Inc.

TECHNIP ENERGIES H1 2026 FINANCIAL RESULTS Managing the near-term; Strengthening long-term fundamentals Order intake of €12.7bn drives backlog to a new high of €25bn, equivalent to three years of revenue H1 impacted by the Middle East situation;...

GlobeNewswire, Inc.

SUNNYVALE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- GSI Technology, Inc. (Nasdaq: GSIT), the inventor of the Associative Processing Unit (APU), a paradigm shift in artificial intelligence (AI) and high-performance compute processing, providing...

GlobeNewswire, Inc.

VANCOUVER, British Columbia, July 30, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS),...

GlobeNewswire, Inc.

BASEL, Switzerland, July 30, 2026 (GLOBE NEWSWIRE) -- Questex, the owners of Fierce Pharma and Fierce Pharma Week, today announces the launch of a new annual event dedicated to the business of pharma.